![ATPγS tetralithium salt (Adenosine-5'-O-3-thiotriphosphate (tetralithium salt); Adenosine 5'-[γ-thio]triphosphate tetralithium salt)](/upload/1124/V75786.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
eIF4
ATPγS tetralithium salt targets P2Y11 receptors, eIF4A, and other ATP-dependent enzymes and processes. As a P2Y11 receptor agonist, it activates this G protein-coupled receptor, which is involved in various physiological processes. As a non-hydrolyzable ATP analog, it can be used to study ATP-dependent processes without being hydrolyzed. It serves as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eIF4A, a key factor in translation initiation. |
|---|---|
| ln Vitro |
Tetralithium salt, or ATPγS, stimulates aggregation and boosts intrinsic fluorescence, both of which raise spinach Rubisco activase activity[1]. ?When added to bronchoalveolar lavage, ATPγS (final blood concentration of 50–100 μM) attenuates the inflammatory response by reducing the accumulation of cells (48%, P < 0.01) and proteins (57%, P < 0.01), as well as the infiltration of neutrophils and the extravasation of Evans blue albumin dye into lung tissue[3].
In vitro, ATPγS tetralithium salt enhances intrinsic fluorescence and induces aggregation, which increases the activity of spinach Rubisco activase. It is used at concentrations of 50-100 μM in various biochemical assays. As a stable ATP analog, it is widely used to study ATP-dependent enzymatic reactions, nucleotide binding, and signaling pathways. |
| ln Vivo |
The maintained lung parenchymal architecture is demonstrated by ATPγS (tetralithium salt, 50 μM final, intravenous)[3]. ?In LPS-treated mice, ATPγS has a dose-dependent influence on EBA extravasation[3].
In vivo activity data for ATPγS tetralithium salt are limited. As a non-hydrolyzable ATP analog, it may have biological effects in animal models when administered exogenously. It has been used to treat pollen grains to determine the inhibitory effect of ATP or its hydrolysis product. Further studies would be needed to evaluate its in vivo pharmacokinetics and pharmacodynamics. |
| Enzyme Assay |
For non-cellular in vitro assays, ATPγS tetralithium salt is evaluated for its interactions with ATP-dependent enzymes. The compound is incubated with purified enzymes such as eIF4A, and its ability to serve as a substrate for nucleotide hydrolysis or RNA unwinding is measured. Binding studies may also be performed to characterize its interactions with nucleotide-binding proteins.
|
| Cell Assay |
For in vitro cellular assays, ATPγS tetralithium salt is used to study ATP-dependent cellular processes. Cells are treated with the compound, and its effects on P2Y11 receptor signaling, nucleotide metabolism, and other ATP-dependent pathways are assessed. The compound's stability against hydrolysis makes it particularly useful for studying processes that would otherwise be affected by ATP hydrolysis.
|
| Animal Protocol |
For in vivo animal studies, ATPγS tetralithium salt would typically be evaluated for its effects on P2Y11 receptor-mediated processes or ATP-dependent pathways. Animals are treated with the compound via various routes of administration, and physiological or biochemical endpoints are measured. The compound's stability against hydrolysis may prolong its effects compared to ATP.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ATPγS tetralithium salt are limited. As a nucleotide analog with a molar mass of 546.98, it is expected to have limited oral bioavailability and is typically administered via injection. The compound is a solid that is white to off-white in color with a purity of ≥90% (HPLC). Further pharmacokinetic studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for ATPγS tetralithium salt are limited. As a nucleotide analog, the compound may have effects on ATP-dependent processes in normal cells. Comprehensive toxicology studies would be required for therapeutic development. The compound is for research use only and not for human use.
|
| References |
|
| Additional Infomation |
ATPγS tetralithium salt is a stable, non-hydrolyzable ATP analog used as a P2Y11 receptor agonist, antioxidant, and neuroprotective agent. It serves as a substrate for eIF4A nucleotide hydrolysis and RNA unwinding activities. The compound has a molecular formula of C₁₀H₁₂Li₄N₅O₁₂P₃S and a molar mass of 546.98. It is used in biochemical and cellular research to study ATP-dependent processes.
|
| Molecular Formula |
C10H12LI4N5O12P3S
|
|---|---|
| Molecular Weight |
546.98
|
| Exact Mass |
547.005
|
| CAS # |
93839-89-5
|
| PubChem CID |
5311341
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
940.5ºC at 760 mmHg
|
| Flash Point |
522.6ºC
|
| LogP |
1.472
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
35
|
| Complexity |
788
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[Li+].[Li+].[Li+].[Li+].C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])OP(=S)([O-])[O-])O)O)N
|
| InChi Key |
DWQFDOIBOYDYKH-KWIZKVQNSA-J
|
| InChi Code |
InChI=1S/C10H16N5O12P3S.4Li/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-28(18,19)26-29(20,21)27-30(22,23)31;;;;/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H,20,21)(H2,11,12,13)(H2,22,23,31);;;;/q;4*+1/p-4/t4-,6-,7-,10-;;;;/m1..../s1
|
| Chemical Name |
tetralithium;[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] dioxidophosphinothioyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (228.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8282 mL | 9.1411 mL | 18.2822 mL | |
| 5 mM | 0.3656 mL | 1.8282 mL | 3.6564 mL | |
| 10 mM | 0.1828 mL | 0.9141 mL | 1.8282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
